CytoMed Therapeutics Ltd (NASDAQ: GDTC)

CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company incorporated in Singapore that focuses on developing cell based immunotherapies for cancer and degenerative diseases. The company leverages proprietary platform technologies that use healthy donor blood cells and induced pluripotent stem cells to manufacture off the shelf products such as CTM N2D iPSC gdNKT CTM GDT and CTM MSC. Its operations are conducted mainly through subsidiaries in Malaysia with plans to expand research and clinical activities in Singapore.

As a pre revenue company, CytoMed Therapeutics Limited does not yet have product sales; its financial resources come from research grants, government funding and collaboration agreements. Notable sources include co funding from the Singapore Ministry of Health through the National Medical Research Council for the ANGELICA trial and an Enterprise Development Grant from Enterprise Singapore to support pre clinical work on the CTM NK program. The company also enters into research collaborations with institutions such as Sengkang General Hospital in Singapore to advance its therapeutic candidates.

CytoMed Therapeutics Limited operates in the competitive field of cell based immunotherapy where companies pursue allogeneic CAR T and related technologies to address solid tumors and other malignancies. Its peers include Allogene Therapeutics Astellas Pharma Bristol Myers Squibb Celyad Oncology Fate Therapeutics Gilead Sciences Novartis and numerous other biopharmaceutical firms that are advancing similar therapeutic approaches. The company differentiates itself by focusing on innate immune cells such as gamma delta T cells and natural killer cells which can be sourced from healthy donors or induced pluripotent stem cells to produce off the shelf products that avoid graft versus host disease and do not require patient specific leukapheresis. Additionally its proprietary platform targets multiple stress associated antigens thereby reducing the risk of antigen escape compared with single antigen CAR T strategies. The firms in house cGMP manufacturing facility in Malaysia further supports cost effective production and quality control for its pipeline candidates.

The company’s eventual customers are expected to be hospitals cancer treatment centers and patients requiring immunotherapy. It currently collaborates with institutions such as National University Hospital Singapore Sengkang General Hospital in Singapore Universiti Malaya in Malaysia and SunAct Cancer Institute in India to advance clinical trials.